Inmune Bio’s Promising Pipeline and Strategic Positioning Support Buy Rating Despite Recent Challenges

Analyst Jason McCarthy of Maxim Group maintained a Buy rating on Inmune Bio, retaining the price target of $8.00.

Jason McCarthy has given his Buy rating due to a combination of factors, primarily focusing on the promising aspects of Inmune Bio’s pipeline despite the recent challenges. The company’s Phase 2 MINDFuL study of XPro, although not meeting its primary endpoint, showed positive trends in a specific Alzheimer’s subgroup with high neuroinflammation, demonstrating potential efficacy and a strong safety profile without amyloid-related side effects. This positions Inmune Bio well for future discussions with the FDA and potential partnerships to advance the program.
Moreover, McCarthy highlights the broader potential within Inmune Bio’s pipeline, including INKmune for prostate cancer and CORDstom for recessive epidermolysis bullosa (RDEB), which could leverage the growing interest in stem cell therapies. The recent approval of similar therapies by other companies suggests a favorable regulatory environment, which could benefit Inmune Bio’s ongoing and future developments. As these programs progress, there is an expectation that the company’s stock could recover and gain value, supporting the Buy recommendation.